Go to article
Posted by CoV Report on December 23, 2021 9:50 amTags: Categories: Global Stories
Merck’s drug, molnupiravir, developed with Ridgeback Biotherapeutics, was shown to reduce hospitalizations and deaths by around 30 per cent.
Your email address will not be published. Required fields are marked *
Comment *
Name *
Email *
Website
Save my name, email, and website in this browser for the next time I comment.
< The Coronavirus Report home
Everything you need to know to stay updated on the Coronavirus
Leave a Reply